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Purpose: To determine whether docosahexaenoic acid can protect against hereditary retinal degenerations in transgenic
mice expressing the V20G, P23H, and P27L (VPP) rhodopsin mutations.
Methods: Female transgenic mice expressing the VPP rhodopsin mutation, known to cause a retinal degeneration, were
bred to male transgenic mice expressing the fat-1 gene, which can convert n6 to n3 polyunsaturated fatty acids (PUFA).
Several weeks before breeding, the female mice were fed a standard diet containing 10% safflower oil (SFO), which is
high in n6 and low in  n3 PUFA (n6/n3=273). Offspring were genotyped and four groups identified: Fat1+/VPP+, Fat1–/
VPP+, Fat1+/VPP–, and Fat1–/VPP–. Dams were maintained on the SFO diet during the nursing period and offspring were
kept on the SFO diet after weaning. At 4, 16, and 28 weeks of age, retinal function was evaluated by electroretinography
(ERG), photoreceptor cell loss was quantified by measuring outer nuclear layer thickness, and rhodopsin levels were
determined. Fatty acid profiles were analyzed in whole retina, plasma, and liver at 4 and 28 weeks of age.
Results: Expression of fat-1 in the absence of dietary n3 PUFA led to the generation of two groups of mice with distinctly
different levels of n3 and n6 PUFA in the three tissues that were analyzed. Already at four weeks of age, the retinas of
fat-1 positive animals had higher levels of n3 PUFA than their wild-type counterparts (23%–29% versus 6.4%–6.5%). In
addition, by four weeks of age, there was a significant loss of rod photoreceptor cells in the VPP mice. Progression of
retinal degeneration occurred with increasing age in VPP positive mice, with photoreceptor cell death occurring in both
inferior and superior regions. Amplitudes of the a- and b-waves of the ERG were significantly reduced with age, with
VPP positive mice showing the greatest change. Rhodopsin content was lower in the VPP transgenic mice. There were
no significant differences in outer nuclear layer thickness or ERG amplitudes between Fat1+/VPP+ and Fat1–/VPP+, or
between Fat1+/VPP–and Fat1–/VPP– mice at any of the three ages.
Conclusions: High levels of retinal docosahexaenoic acid do not protect mice expressing the VPP rhodopsin mutation
from retinal degeneration.
High levels of docosahexaenoic acid (DHA; 22:6n3), a
member of the n3 family of essential polyunsaturated fatty
acids (PUFA), are found in rod photoreceptor outer segments
(ROS) [1]. Studies over several decades have shown that DHA
is essential for maintaining the normal structure and function
of the retina [2–9]. Reduction of DHA in the retina can lead
to diminished retinal electrical responses to light in rodents
[2,3,10], reduced visual acuity in nonhuman primates [4,5],
and  delayed  photoreceptor  development  and  function  in
preterm and term human infants [6,8].
A large number of studies have shown that the levels of
DHA and other n3 and n6 PUFA are reduced in the blood of
patients  with  retinitis  pigmentosa  (RP)  compared  to
appropriate controls, regardless of the mode of inheritance
[11–21], with the greatest differences occurring in patients
with  X-linked  RP  [18].  Animals  with  mutations  causing
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retinal degenerations in humans also have lower levels of n3
and n6 PUFA in their blood [22–26]. In several animal models
of RP, the level of DHA in retinas [26] and rod outer segments
[25,27–29] is lower than that found in controls, suggesting
that the reduced DHA may in some way contribute to or
exacerbate the retinal degeneration in this group of animals.
Indeed, a clinical trial involving humans given DHA found a
subgroup  of  patients  that  responded  positively  to
supplementation [30], although there was no beneficial effect
for the majority of the patients in the study [30,31]. Studies in
X-linked patients have also shown a minimal benefit of DHA
supplementation, again in a sub-group of patients [32]. A
previous  study  in  dogs  with  progressive  rod-cone
degeneration found no benefit in the supplementation of fish
oil [25], which contains large amounts of n3 PUFA. Likewise,
supplementation  of  DHA  in  rats  with  P23H  or  S334ter
rhodopsin mutations did not prevent or slow the loss of rod
photoreceptors [33]. Finally, we recently showed that the level
of DHA in the retinas of mice expressing the mutant human
ELOVL4  transgene  did  not  affect  the  rate  of  retinal
degeneration [34].
Molecular Vision 2010; 16:1669-1679 <http://www.molvis.org/molvis/v16/aa180>
Received 14 February 2010 | Accepted 12 August 2010 | Published 18 August 2010
© 2010 Molecular Vision
1669DHA cannot be synthesized de novo by animals and it,
or its short-chain PUFA precursors, must be furnished in the
diet. The fat-1 gene, cloned from Caenorhabditis elegans
[35], encodes an n3 fatty acid desaturase that can convert n6
to n3 PUFA. Mice expressing the fat-1 transgene, reared on a
diet containing only n6 PUFA, have significantly higher levels
of DHA and other n3 PUFA compared to wild-type controls
in all tissues examined, including the retina [34].
Mice  expressing  an  opsin  transgene  containing  three
(V20G,  P23H,  and  P27L  [VPP])  mutations  near  the  N-
terminus [36] have been used extensively to study inherited
retinal  degeneration  [37–42].  The  P23H  mutation  in  the
rhodopsin gene was the first identified as a cause of autosomal
dominant retinitis pigmentosa in humans [43]. VPP mice have
an age-related progressive photoreceptor degeneration, with
a reduction in the length of the ROS and a decreased number
of nuclei in the outer nuclear layer (ONL) [36,38].
The  purpose  of  the  present  study  was  to  determine
whether providing high levels of DHA in mice by expressing
the  fat-1  protein  can  protect  against  hereditary  retinal
degenerations caused by the VPP rhodopsin mutation. Using
the fat-1 transgenic animals to provide different levels of
retinal DHA eliminated the need to use two diets and allowed
us to use littermates as controls.
METHODS
Animals:  Transgenic  mice  carrying  the  fat-1  gene  of
Caenorhabditis elegans in the C57BL/6J background were
kindly provided by Dr. Jing Kang (Department of Medicine,
Massachusetts General Hospital and Harvard Medical School,
Boston, MA). Heterozygous fat-1 C57BL/6J male mice were
bred  to  heterozygous  female  mice  expressing  the  VPP
transgene (kindly provided by Dr. Connie Cepko, Harvard
University, Boston, MA) in a C57BL/6J background that, for
three weeks before breeding, had been fed a safflower oil
(SFO) diet [44] (Modified AIN-76A Purified Rodent Diet
with 10% SFO by weight, prepared by Dyets, Inc., Bethlehem,
PA). Four different groups of mice, Fat1+/VPP+, Fat1–/VPP+,
Fat1+/VPP–, and Fat1–/VPP– were produced within the same
litters  at  the  Dean  McGee  Eye  Institute  vivarium  and
maintained under 25–75 lux cyclic light (12 h:12 h light-dark
cycle). At weaning, all pups were maintained on the SFO diet
for the entirety of the study. The SFO diet had an n6/n3 ratio
of 273 and was composed of 72 molar % 18:2n6 (Table 1).
Animals  were  cared  for  and  handled  according  to  the
Association  for  Research  in  Vision  and  Ophthalmology
statement for the use of animals in vision and ophthalmic
research.  Protocols  were  reviewed  and  approved  by  the
Institutional  Animal  Care  and  Use  Committees  of  the
University of Oklahoma Health Sciences Center and the Dean
A. McGee Eye Institute.
Genotyping:  Two  millimeter  tail  snips  were  digested
overnight with DirectPCR tail lysis reagent (Viagen Biotech,
Los  Angeles,  CA)  containing  0.3  mg/ml  of  Proteinase  K
(Sigma, St Louis, MO) at 55 °C. The lysates were incubated
at 95 °C for 5 min. Two μl of lysate were used per PCR
reaction in Green Go Taq master mix (Promega, Fitchburg,
WI). The fat-1 transgene was detected using primers (see
TABLE 1. RELATIVE MOLE PERCENTAGE ± STANDARD DEVIATION (N=3–7) OF FATTY ACIDS IN LIVER PHOSPHOLIPIDS, PLASMA PHOSPHOLIPIDS, RETINA TOTAL LIPIDS, AND CHOW TOTAL
LIPIDS.
Age Group 18:2n6 20:4n6 22:4n6 22:5n6 20:5n3 22:6n3 n6/n3
4 wk Plasma F+/V+ 23.2±3.0 8.0±0.9 0.21±0.06 0.50±0.13 0.44±0.10 3.4±0.1 6.9±1.1
  Plasma F-/V+ 21.8±2.0 11.6±2.1 0.75±0.22 3.17±0.62 0 0.5±0.1 62.4±17.2
  Plasma F+/V- 23.9±1.4 8.5±1.1 0.22±0.05 0.62±0.13 0.50±0.18 4.1±1.0 6.8±1.3
  Plasma F-/V- 21.1±1.8 11.7±1.6 0.60±0.21 3.25±0.51 0 0.4±0.1 64.5±8.6
4 wk Liver F+/V+ 21.3±2.1 15.7±2.2 0.3±0.1 0.9±0.7 0.8±0.6 6.7±0.8 5.0±0.4
  Liver F-/V+ 21.0±1.0 19.5±1.4 0.7±0.0 5.1±0.4 0 0.8±0.2 58.4±10.8
  Liver F+/V- 20.8±1.8 15.9±1.0 0.3±0.0 0.9±0.2 0.6±0.3 7.8±1.2 4.6±0.7
  Liver F-/V- 20.3±1.2 19.1±0.9 0.6±0.1 4.9±0.8 0 0.7±0.1 56.3±7.3
4 wk Retina F+/V+ 2.2±0.4 7.2±0.5 0.8±0.2 0.4±0.2 0.5±0.2 21.7±1.9 0.5±0.1
  Retina F-/V+ 1.4±0.1 9.2±0.2 2.6±0.2 15.1±1.6 0 6.4±1.3 4.6±1.0
  Retina F+/V- 1.8±0.7 6.5±0.4 0.9±0.1 0.7±0.1 0.3±0.1 28.2±1.2 0.4±0.1
  Retina F-/V- 1.6±0.1 9.1±0.5 3.0±0.2 18.3±1.4 0 6.2±2.0 5.6±1.7
28 wk Plasma F+/V+ 23.0±4.7 10.8±2.2 0.3±0.1 0.8±0.3 0.4±0.2 4.4±0.4 6.6±0.5
  Plasma F-/V+ 22.4±2.7 13.4±0.6 0.8±0.2 3.2±0.4 0 0.6±0.2 47.0±11.5
  Plasma F+/V- 23.9±1.9 11.8±0.7 0.2±0.1 0.7±0.1 0.3±0.1 5.0±0.6 6.6±1.0
  Plasma F-/V- 21.3±2.0 14.4±1.8 0.7±0.2 3.8±0.4 0 0.7±0.3 48.7±13.7
28 wk Liver F+/V+ 18.6±1.2 18.1±2.9 0.4±0.0 1.2±0.3 0.4±0.3 8.4±1.5 4.5±0.9
  Liver F-/V+ 20.6±1.2 21.5±1.1 0.7±0.1 4.8±0.8 0 1.1±0.3 42.5±8.3
  Liver F+/V- 19.7±0.7 17.8±1.2 0.4±0.0 0.9±0.2 0.6±0.3 8.0±0.6 4.5±0.5
  Liver F-/V- 19.8±2.1 20.2±1.4 0.8±0.2 6.0±1.2 0 1.2±0.5 38.2±10.3
28 wk Retina F+/V+ 1.3±0.1 9.3±0.2 1.0±0.0 0.3±0.1 0.5±0.3 21.7±1.3 0.5±0.0
  Retina F-/V+ 1.4±0.3 10.8±0.7 2.0±0.2 4.3±0.6 0 13.8±1.8 1.4±0.2
  Retina F+/V- 1.4±0.2 6.4±0.3 0.9±0.0 0.3±0.1 0.2±0.0 32.5±0.6 0.3±0.0
  Retina F-/V- 1.6±0.5 8.7±0.4 2.3±0.2 8.3±2.5 0 19.4±3.6 1.2±0.5
Chow Dyets 10% SO 72.4±0.7 0 0 0 0.1±0.0 0 273.5±5.2
             In the table, F indicates fat-1 and V indicates VPP.
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1670Table 2) at 0.5 μM each. The PCR product (251 bp) was
visualized on a 1.25% agarose gel. A separate PCR reaction
was used to detect the VPP transgene. Four primers were used
(Table 2). The PCR products were visualized on a 1.25%
agarose gel. The PCR product of 450 bp identified the VPP
transgene, 750 bp identified actin (internal control), and 300
bp identified an actin pseudogene with varied amplification.
The genetic identity of mice expressing the fat-1 gene was
confirmed by fatty acid analysis. Identity of mice expressing
the  VPP  mutation  was  further  confirmed  by
electroretinography (ERG) and quantitative histology.
Electroretinography: Animals were kept in total darkness
overnight and prepared for the ERG study under dim red light
(Espion E2 ERG System, Diagnosys LLC, Lowell, MA). Mice
were  anesthetized  with  ketamine  (85  mg/kg  bodyweight
intraperitoneal)  and  xylazine  (14  mg/kg  bodyweight
intraperitoneal). One drop of 10% phenylephrine was applied
to  the  cornea  to  dilate  the  pupil  and  one  drop  of  0.5%
proparacaine  HCl  was  applied  for  local  anesthesia.  A
reference electrode was positioned at the mouth and a ground
electrode on the tail. Nine different flash intensities ranging
from 0.001 to 2000 cd.s/m2 were used and ERG responses
from both eyes were recorded with a gold electrode placed on
TABLE 2. THE FOLLOWING PRIMERS WERE USED TO IDENTIFY THE FAT-1 TRANSGENE AND VPP TRANSGENE.
Gene Forward primer (5′-3′) Reverse primer (5′-3′)
Fat-1 CTGCACCACGCCTTCACCACCC ACACAGCAGATTCCAGAGATT
VPP CAGCTGCTCGAAGTGACTCCGACC AGACTGACATGGGGAGGAATTCCCAGA
VPP GACAACGGCTCTGGCCTGGTG GTGTGGCAGGGCATAGCCCTC
Figure 1. Plasma fatty acid composition.
A: The relative mole percentage of n3
and n6 polyunsaturated fatty acids from
total phospholipid extracts of plasma of
Fat1+/VPP+,  Fat1–/VPP+,  Fat1+/
VPP–, and Fat1–/VPP– mice are shown
at  4  weeks  of  age.  B:  Relative  mole
percentages  at  28  weeks  of  age  are
shown. (n=3–7) *p<0.05 fat-1 positive
versus  fat-1  negative.  **p<0.01  fat-1
positive  versus  fat-1  negative.
***p<0.001 fat-1 positive versus fat-1
negative.  F  indicates  fat-1  and  V
indicates VPP.
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1671the cornea. The a-wave and b-wave amplitudes from each eye
were averaged and used for comparison of retinal function.
Outer nuclear layer thickness measurement: Animals were
killed by carbon dioxide asphyxiation following ERG testing.
The right eye was enucleated and the superior margin marked
with  a  dye.  The  eye  was  then  fixed  with  Perfix  (20%
isopropanol, 2% trichloroacetic acid, 4% paraformaldehyde,
and 2% zinc chloride) and embedded in paraffin, and 5 µm
thick sections were taken along the vertical meridian to allow
comparison of all regions of the retina in the superior and
inferior hemispheres. In each hemisphere, ONL thickness was
measured in nine defined areas, starting at the optic nerve head
and extending along the vertical meridian toward the superior
and inferior ora serrata. Measurements were made at 225 µm
intervals. The mean ONL thickness was calculated for the
entire retinal section, as was the ONL thickness of the superior
region of retina, which is most sensitive to the damaging
effects of light.
Lipid analysis: Fatty acid profiles were analyzed in the whole
retina  total  lipids,  plasma  phospholipids,  and  liver
phospholipids from Fat1+/VPP+, Fat1–/VPP+, Fat1+/VPP–, and
Fat1–/VPP– mice by capillary column gas chromatography
with a flame ionization detector [44]. Each analysis was of a
single retina from four to six different mice from each group.
Blood was taken by heart puncture after death and each 100 µl
plasma sample was obtained by centrifuging the heparinized
blood  at  2,000×  g  in  ethylene  glycol  tetraacetic  acid-
containing tubes. Retina and plasma samples were extracted
by a modified Bligh and Dyer procedure, liver samples were
extracted by a modified Folch procedure, and their fatty acids
(as  methyl  esters)  were  analyzed  using  an  Agilent
Technologies 6890 gas chromatograph with flame ionization
detector [44].
Figure 2. Liver fatty acid composition.
A: The relative mole percentage of n3
and n6 polyunsaturated fatty acids from
total phospholipid extracts of liver of
Fat1+/VPP+,  Fat1–/VPP+,  Fat1+/
VPP–, and Fat1–/VPP– mice are shown
at  4  weeks  of  age.  B:  Relative  mole
percentages  at  28  weeks  of  age  are
shown. (n=4–7) *p<0.05 fat-1 positive
versus  fat-1  negative.  **p<0.01  fat-1
positive  versus  fat-1  negative.
***p<0.001 fat-1 positive versus fat-1
negative.
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1672Rhodopsin  assay:  Rhodopsin  assays  were  performed  as
previously described [44]. Briefly, mice were dark-adapted
overnight and killed under dim red light by carbon dioxide
asphyxiation. Single eyes were removed and homogenized in
buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM
EDTA,   2%     (wt/vol)      octylglucoside,          and      50        µM
hydroxylamine. Homogenates maintained in dim red light
were centrifuged at 16,000× g and the soluble fractions were
scanned from 270 to 800 nm in an Ultrospec 3000 UV/Vis
spectrophotometer  (GE  Healthcare,  Piscataway,  NJ).  The
samples were subsequently bleached by exposure to room
light  (~15  min)  and  scanned  again.  The  difference  in
absorbance at 500 nm between pre- and postbleached samples
was  used  to  determine  rhodopsin  content  using  a  molar
extinction coefficient of 42,000 M–1.
Statistical  analysis:  Results  are  expressed  as  the  mean
±standard deviation. Differences were assessed by the Student
t test. A value of p<0.05 was considered significant.
RESULTS
Fatty  acid  composition:  We  analyzed  the  fatty  acid
composition of retina total lipids, plasma phospholipids, and
liver phospholipids from the four groups of mice at 4 and 28
weeks of age (see Table 1) for levels of polyunsaturated fatty
acids. A complete fatty acid analysis of similar animals is
given  in  the  Supplemental  Material  [44].  Fatty  acid
composition of plasma (Figure 1; n=3–7) and liver (Figure 2;
n=4–7) show significantly higher levels of n3 (p<0.01–0.001)
and lower levels of n6 PUFA (p<0.05–0.001) in the fat-1 mice
at 4 weeks (Figure 1A, 2A) and 28 weeks (Figure 1B, Figure
2B)  of  age,  compared  to  their  fat-1  negative  littermates.
Consequently,  the  n6/n3  ratios  for  fat-1  mice  were
significantly lower than their fat-1 negative littermates (Table
1). There were only minor differences in the levels of 18:2n6,
the sole source of PUFA in the diet. The expression of the
transgene had no effect on saturated and monoenoic fatty acid
levels in the plasma or liver.
Figure  3.  Retina  fatty  acid
compositions.  A:  The  relative  mole
percentage of n3 and n6 polyunsaturated
fatty acids from total lipid extracts of
retina  of  Fat1+/VPP+,  Fat1–/VPP+,
Fat1+/VPP–, and Fat1–/VPP– mice are
shown at 4 weeks of age. B: Relative
mole percentages at 28 weeks of age are
shown. (n=4–6) **p<0.01 fat-1 positive
versus fat-1 negative. ***p<0.001 fat-1
positive versus fat-1 negative.
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1673The high levels of 18:2n6 in plasma and liver were not
found in the retina (Figure 3), where the major fatty acids were
C-20 and C-22 PUFA (n=4–6). At 4 (Figure 3A) and 28
(Figure 3B) weeks of age, the fat-1 mice in both groups had
significantly higher percentages of 20:5n3 (p<0.01–0.001)
and 22:6n3 (p<0.001), and significantly lower percentages of
20:4n6  (p<0.01–0.001),  22:4n6  (p<0.001),  and  22:5n6
(p<0.001), compared to the fat-1 negative mice (Table 1). All
four groups had a significantly higher percentage of 22:6n3
(p<0.001) and lower percentage of 22:5n6 (p<0.001) at the
age of 28 weeks than at 4 weeks (Table 1). With the exception
of 22:6n3 in the four-week-old retinas, there was significantly
less  22:5n6  and  22:6n3  in  the  mice  expressing  the  VPP
transgene, a finding we have obtained in other mouse [27,
28] and rat [29,33] retinas that express a mutant gene involved
in retinal degeneration.
Retinal structure: Retinal structure was examined along the
vertical  meridian  from  inferior  to  superior  ora  serrata.
Sections from central superior retina are shown in Figure 4.
At four weeks of age, the ONL thickness in both VPP+ groups
was already reduced from the normal 10–11 rows to 6–8 rows
(Figure 4A,B). By 16 weeks, more than half of photoreceptor
nuclei were lost in VPP+ groups (Figure 4E,F). Even greater
retinal degeneration is evident in the 28-week-old VPP+ mice
(Figure 4I,J). There was some age-related loss of rod nuclei
in the VPP- mice (Figure 4C,D,G,H,K,L), but not to the extent
seen in the VPP+ mice. Examination of the sections did not
show  any  effect  of  22:6n3  level  on  the  rate  of  retinal
degeneration in the VPP+ mice.
The progression of retinal degeneration along the vertical
meridian with increasing age was quantified in the “spider”
graph  in  Figure  5A,C,E  (n=10).  There  was  a  significant
reduction  in  ONL  thickness  in  both  inferior  and  superior
regions of both groups of four-week-old VPP+ mice (Figure
5A). Means of ONL thickness taken from 14 sites along the
vertical meridian (seven superior and seven inferior of the
optic nerve head) were averaged for each age group. There
were no significant differences in ONL thickness between
Fat1+/VPP+  and  Fat1–/VPP+  or  between  Fat1+/VPP–  and
Fat1–/VPP– mice at the three ages examined (Figure 5B,D,E).
There was an age-related loss of rod nuclei in all groups, which
was significantly greater in the VPP+ mice. However, there
was no significant effect of retinal 22:6n3 levels on the rate
of rod photoreceptor degeneration.
Retinal function: Retinal function was determined by ERG.
Nine intensities were used and the responses from both eyes
Figure 4. Retinal structure. A-D: Retinal
structure is revealed by representative
photomicrographs  from  the  central
superior  retina  from  Fat1+/VPP+,
Fat1–/VPP+,  Fat1+/VPP–,  and  Fat1–/
VPP–  mice  at  4  weeks  of  age.  E-H:
Photomicrographs at 16 weeks of age
are shown. I-L: Photomicrographs at 28
weeks of age are shown. Magnification
bar equal to 50 microns.
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1674were recorded simultaneously and averaged. The a- and b-
wave amplitudes at a saturating flash intensity of 1,000 cd.s/
m2 are shown in Figure 6 (n=10). There was a significant
reduction in amplitudes with the age, with VPP+ mice showing
the greatest change. Compared to four-week-old mice (Figure
6A), the a-wave amplitude in 16-week-old VPP+ mice was
reduced by 24%–29% (Figure 6C) and by greater than 60%
in  28-week-old  mice  (Figure  6E).  The  a-wave  was  also
reduced in VPP– mice by 15%–17% at 16 weeks and 29%–
36% at 28 weeks. The loss of a-wave amplitude was greater
in the VPP+ mice than in the VPP– mice. There was no effect
of retinal 22:6n3 levels on the a-wave amplitude in VPP+ and
VPP– mice.
Among VPP+ transgenic mice, b-wave amplitudes were
reduced by 17%–29% at 16 weeks of age (Figure 6D) and by
over 50% at 28 weeks of age (Figure 6F). In VPP– mice, the
b-wave amplitudes were reduced by 18%–19% at 16 weeks
(Figure 6D) and 32%–35% at 28 weeks (Figure 6F). There
were no significant differences in b-wave amplitudes between
Fat1+/VPP+  and  Fat1–/VPP+  or  between  Fat1+/VPP–  and
Fat1–/VPP– mice at any age.
Rhodopsin  levels:  Figure  7  shows  the  retinal  content  of
bleachable rhodopsin in detergent extracts of whole mouse
eyes at age of four weeks (Figure 7A, n≥6), 16 weeks (Figure
7B, n≥4), and 28 weeks (Figure 7C, n≥3). VPP transgenic
mice had low amounts of rhodopsin. There were no significant
differences between Fat1+/VPP+ and Fat1–/VPP+ or between
Fat1+/VPP–  and  Fat1–/VPP–  mice  at  any  of  the  three  age
groups. Statistical analysis was not possible at 28 weeks of
age as no rhodopsin was detectable in Fat1+/VPP+ mice at this
age.
DISCUSSION
In 1993, Naash and colleagues [36] generated a transgenic
mouse with three point mutations in rhodopsin (V20G, P23H,
and P27L; termed VPP) that resembles the P23H mutation
found in many humans with autosomal dominant retinitis
pigmentosa [43]. VPP mice have reduced levels of rhodopsin
and  amplitudes  of  a-  and  b-waves  of  their  scotopic  ERG
compared to nontransgenic littermates [36]. They also have
structural  abnormalities,  including  shortened  rod  outer
segments and progressive loss of rod nuclei [36]. The VPP
mice  used  in  the  present  study  displayed  all  of  these
characteristics.
Over the last three decades, studies by many laboratories
[11–13,15–19,21], including our own [14,20], have shown
that patients with retinitis pigmentosa and Usher’s disease
have lower levels of 22:6n3 and other PUFA in plasma, serum,
Figure  5.  Quantification  of
morphological  changes.  The
quantification  of  morphological
changes are shown by measurements of
outer  nuclear  layer  (ONL)  thickness
along the vertical meridian of the eye in
Fat1+/VPP+,  Fat1–/VPP+,  Fat1+/
VPP–,  and  Fat1–/VPP–  mice
maintained in 20 lx cyclic light (n=10).
A, C, E: Plots show ONL thickness of
transgenic mice at 4, 16, and 28 weeks
of age. B, D, F: Histograms show the
average ONL thickness in the three age
groups.
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1675and red blood cells. The cause of the reduced PUFA is not
known, but it does not appear to be related to diet, exercise,
or type of inheritance. We have reported that the levels of
DHA are lower in the retinas of dogs [25,26] and in rod outer
segments of mice [27,28] and rats [29] that express transgenes
of  naturally  occurring  mutations  that  cause  retinal
degenerations  in  humans.  However,  attempts  to  slow  the
degeneration in dogs with progressive rod-cone degeneration
by providing fish oil were not successful [25]. Likewise, when
rats expressing the P23H or S334ter rhodopsin transgenes
were raised on the SFO diet, which reduced their ROS DHA
by 50%, there was no exacerbation of rod photoreceptor cell
loss [29].
Mammalian species cannot naturally produce n3 from n6
PUFA and must therefore depend on a dietary source for these
essential fatty acids. The fat-1 transgenic mouse expresses an
n3 fatty acid desaturase, derived from C. elegans [35], that
can convert n6 to n3 PUFA by introducing a double bond into
n6 PUFA at the n3 position of their hydrocarbon chains [45,
46]. This genetic manipulation allows significant fatty acid
compositional changes to be made in cellular lipids in mice
fed the same diet and born to the same group of dams. The
SFO diet, which contains mainly 18:2n6 and only traces of n3
PUFA, has been used in many studies [2,44,47–49] to reduce
n3 PUFA in membrane phospholipids. All of the mice used in
the present study were fed the SFO diet, with the dams started
several  weeks  before  breeding.  This  ensured  that,  during
development and the nursing period following birth, the pups
were supplied primarily with n6 PUFA, since fatty acids in
the  blood  and  the  milk  of  the  dam  reflect  the  fatty  acid
composition of their diet.
In the present study, we used genetic manipulation rather
than diet to alter the DHA content of the retina of a mouse
model of human RP. Our results show a significantly higher
level of DHA (p<0.001) in the fat-1 positive mice compared
to the fat-1 negative mice in the retina, plasma, and liver. The
retina had the highest levels of DHA, which were comparable
to those reported previously for fat-1 positive mice [34,44]
and for mice [27,28] and rats [33,49] fed diets containing n3
PUFA. Retinas of fat-1 negative mice fed the SFO diet had
about half the DHA levels of the fat-1 positive mice, but these
reduced  DHA  levels  did  not  result  in  changes  in  retinal
structure or function as we recently reported [44]. In this
earlier study, dietary n3 deficiency in fat-1 negative animals
Figure 6. Evaluation of retinal function
by  electroretinography.  Evaluation  of
retinal function by electroretinography
was  determined  by  taking
measurements  of  a-  and  b-wave
amplitudes in Fat1+/VPP+, Fat1–/VPP
+, Fat1+/VPP–, and Fat1–/VPP– mice
(n=10). A, C, E: The average a-wave
amplitudes are shown at 4, 16, and 28
weeks of age, respectively. B, D, F: The
corresponding  b-wave  amplitudes  are
shown.
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1676resulted  in  only  subtle  electroretinographic  changes  (e.g.,
decreased a-wave sensitivity and increased a-wave implicit
times),  but  did  not  result  in  profound  changes  in  ERG
amplitudes or retinal structure unless stressed by intense light
exposure [44].
The level of DHA in the retinas of VPP mice had no
influence on the rate of loss of photoreceptor cells. There were
no  functional  or  structural  differences  between  the  fat-1
positive and negative mice either in the presence or absence
of the VPP transgene. Thus, the presence of a twofold higher
content of DHA in the retinas of mice expressing a mutation
causing human RP could not rescue the rod photoreceptor
cells from death. We reached a similar conclusion in a recent
Figure  7.  Rhodopsin  content  of  transgenic  mouse  retinas.  A:
Rhodopsin content of eyes from Fat1+/VPP+, Fat1–/VPP+, Fat1+/
VPP–, and Fat1–/VPP– mice was determined at age of 4 weeks
(n≥6). B: Rhodopsin content shown at 16 weeks (n≥4). C: Rhodopsin
content shown at 28 weeks (n≥3).
study in which mice expressing a transgene of human mutant
ELOVL4 gene were bred with fat-1 mice to generate animals
with high and low levels of retinal DHA [34]. A DHA-derived
docosanoid  product,  neuroprotectin  D1,  has  potent
neuroprotective  effects  through  the  suppression  of
inflammation (reviewed in [50]). The lack of protective effect
of increased DHA levels on the progression of degeneration
in the VPP mouse suggests the possibility that inflammation
does not contribute significantly to the pathogenesis of this
particular model. Therefore, on the basis of several studies
showing no beneficial effects of DHA on the survival of
retinal rod photoreceptors in mice expressing mutant genes or
mutant transgenes, we conclude that DHA does not rescue
these cells from degeneration.
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